During the past decade, The University of Kansas Cancer Center - Investigational Drug Services conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "The University of Kansas Cancer Center - Investigational Drug Services" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator, "Medivation, Inc." with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "The University of Kansas Cancer Center - Investigational Drug Services" are "BRAF V600E-mutant Metastatic Colorectal Cancer" (1 trials), "BRCA 1 Gene Mutation" (1 trials), "BRCA 2 Gene Mutation" (1 trials), "Breast Neoplasms" (1 trials) and "Cancer of the Prostate" (1 trials). Many other conditions were trialed in "The University of Kansas Cancer Center - Investigational Drug Services" in a lesser frequency.

Most popular intervention types in "The University of Kansas Cancer Center - Investigational Drug Services" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "5-Fluorouracil" (1 trials), "Binimetinib" (1 trials), "Cetuximab" (1 trials), "Encorafenib" (1 trials) and "Enzalutamide" (1 trials). Other intervention names were less common.

The vast majority of trials in "The University of Kansas Cancer Center - Investigational Drug Services" are 2 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The University of Kansas Cancer Center - Investigational Drug Services". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in The University of Kansas Cancer Center - Investigational Drug Services, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in The University of Kansas Cancer Center - Investigational Drug Services, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".